We are on a mission to
outsmart cancer resistance.

Theseus is developing next-generation tyrosine kinase inhibitors (TKIs) to transform the way cancer is treated.

Learn Moredown

Our targeted, small molecule therapies are designed to address treatment-resistance in cancer.

LEARN MORE

Working to deliver best-in-class pan-variant tyrosine kinase inhibitors to cancer patients.

We are developing a pipeline of TKIs designed to inhibit all major cancer-causing and drug resistance mutations in clinically significant tyrosine kinase targets.

LEARN MORE

View our latest news.

View All

Jan 05, 2023

Theseus Pharmaceuticals Highlights Key Anticipated 2023 Milestones and Announces BCR-ABL as Target for Third Development Program

Nov 03, 2022

Theseus Pharmaceuticals Announces Business and Pipeline Highlights and Reports Third Quarter 2022 Financial Results

Oct 26, 2022

Theseus Pharmaceuticals Presents Preclinical Data Characterizing THE-349, its Fourth-Generation EGFR Inhibitor in Development for NSCLC, at the 34th EORTC-NCI-AACR Symposium
We are building a community working to outsmart cancer resistance. Join us!

SEE OPEN ROLES